ARHGAP10, Transcriptionally Regulated by Sodium Butyrate, Promotes Ferroptosis of Ovarian Cancer Cells
Frontiers in Bioscience-Landmark · 2024
DOI: 10.31083/j.fbl2905167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Huihui Ke und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 201399 Shanghai, China. Hauptthemen laut MEDLINE: Butyric Acid, Ferroptosis, Gene Expression Regulation, Neoplastic, GTPase-Activating Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Development Fund of Shanghai Pudong, Key Specialty Construction Project of Pudong Health and Family, Project of Key Medical Specialty and Treatment Center of Pudong Hospital of Fudan University.
Abstract (Originalsprache)
Background
Ovarian cancer is a highly lethal gynecologic malignancy. ARHGAP10, a member of Rho GTPase-activating proteins, is a potential tumor suppressor in ovarian cancer. However, its role and the involved mechanism need further examination. Here, we investigated whether ARHGAP10 is also associated with ferroptosis.
Methods
Lentivirus infection was used for gene overexpression or silencing. Real-time polymerase chain reaction (RT-PCR) and Western blot were used to assess mRNA and protein levels, respectively. Cell viability was assessed by Cell Counting Kit-8 (CCK-8) assay. Lipid reactive oxygen species level was measured by flow cytometry. A tumorigenicity assay was performed to evaluate tumor growth in vivo, and sections of mouse tumor tissues were examined by immunofluorescence microscopy. Chromatin Immunoprecipitation (ChIP) assay was used to assess the binding of H3K9ac to the promoter region of ARHGAP10.
Results
ARHGAP10 overexpression promoted ferroptosis in ovarian cancer cells, resulting in decreased cell viability, and increased lipid reactive oxygen species (ROS) level. Further, it decreased and increased GPX4 and PTGS2 expression, respectively, and also induced suppression of tumor growth in mice. Fer-1, a potent inhibitor of ferroptosis, suppressed the above effects of ARHGAP10. Contrarily, ARHGAP10 silencing alleviated ferroptosis in ovarian cancer cells, which was reversed by RSL3, a ferroptosis-inducing agent. Lastly, sodium butyrate (SB) was found to transcriptionally regulate ARHGAP10, thereby also contributing to the ferroptosis of ovarian cancer cells.
Conclusions
Our results suggest that SB/ARHGAP10/GPX4 is a new signaling axis involved in inducing ferroptosis in ovarian cancer cells and suppressing tumor growth, which has potential clinical significance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 201399 Shanghai, China.
Förderung
- Science and Technology Development Fund of Shanghai Pudong
- Key Specialty Construction Project of Pudong Health and Family
- Project of Key Medical Specialty and Treatment Center of Pudong Hospital of Fudan University
Zitieren
APA
Ke, H., Shao, J., Hu, J., Song, X., Han, H., Zhu, Z., Zhou, X., Chen, L., & Shan, Y. (2024). ARHGAP10, Transcriptionally Regulated by Sodium Butyrate, Promotes Ferroptosis of Ovarian Cancer Cells. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2905167
Vancouver
Ke H, Shao J, Hu J, Song X, Han H, Zhu Z, et al. ARHGAP10, Transcriptionally Regulated by Sodium Butyrate, Promotes Ferroptosis of Ovarian Cancer Cells. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2905167
BibTeX
@article{Ke2024,
author = {Ke, Huihui and Shao, Juan and Hu, Jiachang and Song, Xumin and Han, Hongyu and Zhu, Zhanpeng and Zhou, Xinying and Chen, Li and Shan, Ying},
title = {ARHGAP10, Transcriptionally Regulated by Sodium Butyrate, Promotes Ferroptosis of Ovarian Cancer Cells},
journal = {Frontiers in Bioscience-Landmark},
year = {2024},
doi = {10.31083/j.fbl2905167}
}
EUVIMED